Another thread on the risk of sublethal mutagenesis (on the virus, not the human!) from molnupiravir:https://twitter.com/michaelzlin/status/1464424333246447620 …
With so many on the FDA panel raising this, specifically, as a significant enough concern, I'd like someone to tell us more about all this before approval, including how we'd get that kind of data/clarity.
-
-
And while Omicron has affected my thinking on flexibility of ACE2 interface (bad for mutagenesis hypothesis), it's also prob compromised our best antivirals: mAb's. Therapies that mimic vaccines = not ideal. Orthogonal targets (protease, polymerase) = better. Nothing's easy.
-
I'm not sure who can "tell us" more, but I'd sure love to learn from them!
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
1/15